Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Moderate-to-severe Chronic Plaque Psoriasis: early-phase trial registry
A small indexed set (4 trials) with no open enrollment listed right now.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · none currently recruiting · #4,115 of 28,707 conditions by registered trial count
Moderate-to-severe Chronic Plaque Psoriasis: 4 US clinical trials tracked, none currently recruiting.
Moderate-to-severe Chronic Plaque Psoriasis is the subject of 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Biocon Biologics UK, running 1 of these trials.
Enrollment posture brief
Registry condition moderate-to-severe-chronic-plaque-psoriasis
OPEN 0 | RECR 0% | LATE 1 | EARLY 3 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Moderate-to-severe Chronic Plaque Psoriasis has no open enrollment in this registry pull (4 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Moderate-to-severe Chronic Plaque Psoriasis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Moderate-to-severe Chronic Plaque Psoriasis is recruiting below its size-band peers.
0 of 4 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
4 total, page 1 of 1
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
Sun Pharmaceutical Industries Limited
NCT03997786
Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
Biocon Biologics UK
NCT05335356
A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis
Genzyme, a Sanofi Company
NCT00601107
Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients
AbGenomics B.V Taiwan Branch
NCT01855880
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Moderate-to-severe Chronic Plaque Psoriasis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Moderate-to-severe Chronic Plaque Psoriasis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Moderate-to-severe Chronic Plaque Psoriasis page
4 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Moderate-to-severe Chronic Plaque Psoriasis trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Biocon Biologics UK sponsors the most Moderate-to-severe Chronic Plaque Psoriasis trials on record, review their full trial history before evaluating a specific study. See Biocon Biologics UK's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Moderate-to-severe Chronic Plaque Psoriasis condition card totals 4 registered trials; most-linked intervention Placebo; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.